IGC Pharma, Inc. (IGC)

IGC Pharma Statistics

Total Valuation

IGC Pharma has a market cap or net worth of $26.43 million. The enterprise value is $24.57 million.

Market Cap	26.43M
Enterprise Value	24.57M

Important Dates

The last earnings date was Tuesday, November 12, 2024, after market close.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

IGC Pharma has 77.45 million shares outstanding. The number of shares has increased by 29.63% in one year.

Current Share Class	77.45M
Shares Outstanding	77.45M
Shares Change (YoY)	+29.63%
Shares Change (QoQ)	+17.90%
Owned by Insiders (%)	9.56%
Owned by Institutions (%)	21.37%
Float	70.04M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	19.50
Forward PS	56.92
PB Ratio	3.46
P/TBV Ratio	4.63
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	20.77
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.52, with a Debt / Equity ratio of 0.04.

Current Ratio	1.52
Quick Ratio	0.58
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -117.06% and return on invested capital (ROIC) is -52.51%.

Return on Equity (ROE)	-117.06%
Return on Assets (ROA)	-43.37%
Return on Capital (ROIC)	-52.51%
Revenue Per Employee	$17,657
Profits Per Employee	-$187,597
Employee Count	67
Asset Turnover	0.09
Inventory Turnover	0.25

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +11.85% in the last 52 weeks. The beta is 1.29, so IGC Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.29
52-Week Price Change	+11.85%
50-Day Moving Average	0.37
200-Day Moving Average	0.41
Relative Strength Index (RSI)	33.35
Average Volume (20 Days)	229,694

Short Selling Information

The latest short interest is 1.22 million, so 1.58% of the outstanding shares have been sold short.

Short Interest	1.22M
Short Previous Month	1.65M
Short % of Shares Out	1.58%
Short % of Float	1.75%
Short Ratio (days to cover)	2.29

Income Statement

In the last 12 months, IGC Pharma had revenue of $1.18 million and -$12.57 million in losses. Loss per share was -$0.18.

Revenue	1.18M
Gross Profit	665,000
Operating Income	-9.33M
Pretax Income	-13.30M
Net Income	-12.57M
EBITDA	-8.69M
EBIT	-9.33M
Loss Per Share	-$0.18

Balance Sheet

The company has $1.55 million in cash and $304,000 in debt, giving a net cash position of $1.24 million or $0.02 per share.

Cash & Cash Equivalents	1.55M
Total Debt	304,000
Net Cash	1.24M
Net Cash Per Share	$0.02
Equity (Book Value)	7.38M
Book Value Per Share	0.10
Working Capital	1.45M

Cash Flow

In the last 12 months, operating cash flow was -$4.86 million and capital expenditures -$150,000, giving a free cash flow of -$5.01 million.

Operating Cash Flow	-4.86M
Capital Expenditures	-150,000
Free Cash Flow	-5.01M
FCF Per Share	-$0.06

Margins

Gross Margin	56.21%
Operating Margin	-788.25%
Pretax Margin	-1,062.47%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-530.89%

Dividends & Yields

IGC Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-29.63%
Shareholder Yield	-29.63%
Earnings Yield	-48.69%
FCF Yield	-19.41%

Analyst Forecast

The average price target for IGC Pharma is $3.63, which is 963.89% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$3.63
Price Target Difference	963.89%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on April 19, 2013. It was a reverse split with a ratio of 0.1:1.

Last Split Date	Apr 19, 2013
Split Type	Reverse
Split Ratio	0.1:1

Scores

IGC Pharma has an Altman Z-Score of -13.33 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-13.33
Piotroski F-Score	4